Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study
A legfontosabb adatok
- Ki végzi
- Ohio State University Comprehensive Cancer Center
- Hol
- Columbus (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 8 fő vett részt
- Kezdés
- 2023. jún. 2.
- Befejezés
- 2024. jan. 26.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Anesthesia Procedure
- General Anesthesia Procedure
- Resection
- A regiszteradat frissítve
- 2025. július 10.
- Miért állt le
- Principal investigator departed sponsoring organization
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Adults: ≥18 years old on the day of consent
- Non-metastatic pancreatic adenocarcinoma
- Able to provide consent
- ECOG performance status of 0 or 1
- Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test for the patient at the time of surgery
- Ability to understand and the willingness to sign a written informed consent document
Ki nem vehet részt
- Previous identified allergy or hypersensitivity to any component of the study treatment
- Major surgery within 2 months before enrollment. Complete healing from major surgery must have occurred 1 month before enrollment. Complete healing from minor surgery (eg, simple excision, tooth extraction) must have occurred at least 7 days before enrollment. Subjects with clinically relevant complications from prior surgery are not eligible; Patients who undergo reoperation during their initial hospitalization will be censored at the time of reoperation
- Allergies to eggs, egg products, soybeans, or soy products
- Personal or first degree relative with a history of malignant hyperthermia
- Has a known additional malignancy that is expected to require active treatment within two years, or is likely to be life-limiting in the opinion of the treating investigator. Superficial bladder cancer, non-melanoma skin cancers, or low-grade prostate cancer not requiring therapy would not exclude participation in this trial
- Uncontrolled intercurrent illness including, but not limited to: Symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or lactating females
- Prisoner status
Helyszínek itt: Egyesült Államok
- Ohio State University Comprehensive Cancer CenterColumbus, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This phase II trials studies the impact of total intravenous anesthesia (TIVA) following cancer surgery. Surgery and the anesthesia delivered causes physiologic stress and trauma resulting in immune suppression. TIVA is an alternative method of general anesthesia that has several benefits over volatile inhalation agents such as reducing nausea, vomiting, and opioid consumption, and promotes earlier return of bowel function following surgery. In addition, TIVA is less immunosuppressive than inhalational agents and has been shown to decrease cancer cell proliferation, migration, and metastasis formation. Giving TIVA during cancer-directed abdominal surgery may decrease the immunosuppressive state in the peri-surgical period.
A vizsgálat 2 csoportja
- Arm I (surgical resection with TIVA)A vizsgált kezelés
Patients undergo surgical resection with TIVA.
Kezelés: Anesthesia Procedure és Resection
- Arm II (surgical resection with inhaled volatile anesthetics)Már használt kezelés, összehasonlításként
Patients undergo surgical resection with inhaled volatile anesthetics.
Kezelés: General Anesthesia Procedure és Resection
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- The Impact of Total Intravenous Anesthesia Following Cancer Surgery (TIVACS) Study
- A regiszteradat frissítve
- 2025. július 10.